[Form 4] Zivo Bioscience, Inc. Insider Trading Activity
Zivo Bioscience, Inc. (ZIVO) director and 10% owner Christopher D. Maggiore was granted 1,075 nonstatutory stock options on 10/02/2025 under the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees of $10,964.38.
Rhea-AI Filing Summary
Zivo Bioscience, Inc. (ZIVO) director and 10% owner Christopher D. Maggiore was granted 1,075 nonstatutory stock options on 10/02/2025 under the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees of $10,964.38. The options have an exercise price of $12.03, are exercisable immediately on 10/02/2025, and expire on 10/02/2035. The filing shows the underlying common stock amount as 1,075 shares and reports the transaction on a Form 4 signed 10/06/2025. This is a routine director compensation award recorded as equity rather than cash.
Positive
- None.
Negative
- None.
Insights
Grant signals routine non-employee director compensation paid in equity.
The option award of 1,075 options replaces a cash retainer of $10,964.38, aligning non-employee director pay with shareholder outcomes while conserving cash. The options are nonstatutory, immediately exercisable on 10/02/2025, and expire on 10/02/2035.
Key dependencies include the company stock price relative to the $12.03 exercise price and potential dilution of 1,075 shares. Monitor reported outstanding shares or future grants for dilution trends over the next 12 months.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Nonstatutory Stock Options to buy Common Stock | 1,075 | $10.20 | $11K |
Footnotes (1)
- F1. This option was issued to the reporting person pursuant to the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees of $10,964.38
AI-generated analysis. How Rhea-AI works. Not financial advice.